Published Aug 29, 2026 | 1:55 PM ⚊ Updated Aug 29, 2026 | 1:55 PM
Bengaluru ‘Peptide Party’ cancelled after Karnataka FSDA seeks details. (iStock)
Synopsis: A “Peptide Party” scheduled in Bengaluru’s Koramangala on August 29 was cancelled after Karnataka’s Food Safety and Drug Administration sought detailed information from organiser Upsurge Labs LLP on the identity, composition, regulatory status, intended use and proposed administration of peptide products.
A proposed “Peptide Party” in Bengaluru’s Koramangala has been cancelled after Karnataka’s Food Safety and Drug Administration (FSDA) sought extensive details from the organisers on the peptide preparations that were to be associated with the event, including their composition, source, regulatory status, intended use and whether they would be supplied or administered to participants.
The invite-only event, organised by Upsurge Labs LLP, was scheduled for 29 August and had been promoted online with references to “peptide tastings”, music, food, games and conversations around peptides.
The Karnataka FSDA took note of the publicity material and initiated an enquiry. In its August 28 public advisory, the department said the authorised representatives of Upsurge Labs LLP had communicated, following the enquiry, that the event “stands cancelled”. The department also said the organisers had sought time to submit documents regarding the event and that suitable time had been given.
The cancellation was confirmed by the organisers.
“An update on Peptide Party: The response to this has been WAY bigger than we anticipated – genuinely didn’t expect this level of love. In the process, the Karnataka FDA reached out to us under due process of law, and we’re cooperating fully with their office to make sure this is done right. Which is why the event is currently cancelled – notice attached. Building something this new means occasionally slowing down to do it properly. Ciao,” said Anushka Singh, associated with Upsurge Labs.
Also Read: Oxygen bars promise clean air and wellness, but doctors say there is little evidence of benefit
The regulator’s concern was not simply that the event involved peptides.
In its notice to the organisers, the FSDA said the publicity material “appears to indicate” that peptide preparations or products may be “promoted, displayed, supplied, distributed, recommended, administered or otherwise made available to participants” in connection with the proposed event.
But the department said the “exact identity, composition, source, regulatory classification, intended use and regulatory status” of the preparations referred to in the publicity material had not been established.
That uncertainty appears to have been central to the FSDA’s intervention.
The department sought complete particulars of every peptide preparation or product proposed to be promoted, displayed, supplied, distributed, administered or otherwise made available at the event.
The information sought included the product or brand name, composition, strength or concentration, dosage form, route of administration, recommended dose and frequency, batch or lot numbers, manufacturing and expiry dates, packaging and promotional material.
The FSDA also sought details of manufacturers, suppliers and importers, including manufacturing licences, manufacturing facilities, import documents, country of origin, purchase invoices and supply-chain records.
The regulatory issue becomes more significant because the FSDA did not assume that all peptide products would have the same legal status.
The department said certain peptide preparations, “depending upon their composition, presentation, intended use, claims and manner of administration”, may fall within the regulatory framework applicable to “drugs” under the Drugs and Cosmetics Act, 1940.
The FSDA therefore asked the organisers to clarify whether each preparation was considered a drug and, if so, provide details of the relevant manufacturing licence, product approval, composition, dosage, indications, route of administration and prescribing information.
It also pointed to the possibility that some preparations could qualify as new drugs, in which case the relevant provisions governing approval, manufacture and marketing would apply.
This is one of the key reasons the cancellation should not be interpreted simply as a regulator declaring peptides unsafe. The FSDA was seeking to establish what products were actually involved and which regulatory framework applied to them.
Also Read: H1N1 surge raises another concern: Are patients reaching for antibiotics on their own?
The regulator also questioned the claims associated with the peptide preparations.
The FSDA sought details of therapeutic or health-related claims concerning “weight management, muscle growth or recovery, anti-ageing, sexual and reproductive health, metabolic health, diabetes, obesity, inflammation, tissue repair, hormonal effects” and enhancement of athletic or physical performance.
The organisers were asked to provide scientific evidence, published clinical studies and other supporting material for such claims.
This matters because a peptide having a biological effect does not automatically mean that it has been established as a safe or effective treatment for a particular condition.
Peptides are short chains of amino acids and include molecules with important functions in the human body. Some approved medicines are peptide-based. The regulatory concern in Bengaluru was instead about the specific products and claims associated with the event, and whether they had the required evidence and approvals.
Another major question raised by the FSDA was whether the event would involve participants actually receiving peptide preparations.
The department sought clarification on whether the products would be sold, distributed free of cost, provided as samples or administered to participants, including through injections.
If administration was proposed, the FSDA sought details of the persons administering the preparations, their qualifications and registration, the place and manner of administration, dosage, consent procedures, medical supervision and arrangements for managing emergencies or adverse events.
The regulator also sought relevant FSSAI documents if any products were being presented as health supplements or nutraceuticals.
In effect, the department was asking a basic regulatory question: Was this merely an educational gathering, or could participants be exposed to peptide products in a setting where drug, food or clinical regulations applied?
Upsurge Labs founder Sowmay Jain said the event was never intended to involve administration or sale of peptide products.
“It was an educational meetup – no injectables, no products, no prescriptions. Just curious people discussing the science behind a class of molecules the FDA is actively reviewing – the same class that includes some of the most prescribed drugs in the world today. The kind of meetup that happens in SF every weekend,” Jain said.
He added that the organisers’ “intent was always awareness, never harm”. Jain also welcomed the regulatory engagement, saying: “This is not pre-2014 India. The officials we are seeing are engaged, serious, and acting in good faith to protect people. That’s exactly what regulators should do, and I respect it.”
He said regulation could help establish the emerging sector rather than hinder it.
“Regulation done right isn’t the enemy of science – it’s what makes an industry legitimate and durable,” Jain said.
He further said the company was willing to work with regulators to build frameworks for the emerging biotechnology sector.
“We are happy to work with the authorities, collaboratively and transparently, to help build the frameworks this industry needs. Builders and regulators on the same side of the table,” he said.
The controversy comes as peptides have gained popularity in online wellness, fitness and longevity communities.
While some peptide-based medicines are established treatments, other compounds promoted online are experimental, inadequately studied or not approved for the purposes for which they are marketed.
Aakanksha Sadekar Chauhan of EkaantCare criticised what she described as unregulated peptide use, while distinguishing it from medically supervised GLP-1 treatment.
“I am a huge supporter of GLP1 supervised under a licensed medical doctor’s care but this American madness of unregulated drug use is something I can never support,” she said.
Another response to the cancellation said: “Let us not speculate about drugs which are not evidence based. I will always support research on peptides with informed consent of patients. But cannot support non evidence based practices.”
The distinction is important. Peptides as a class are not inherently dangerous. Insulin, for example, is a peptide hormone, while several modern medicines used for diabetes and obesity act through peptide pathways.
The concern is with products whose safety, efficacy, quality, dosage and regulatory status have not been adequately established, particularly when they are promoted for medical or performance-related purposes outside appropriate supervision.
The FSDA’s August 28 advisory does not record a final finding that Upsurge Labs committed an offence. It records that the organisers communicated that the event had been cancelled after the enquiry and that they had requested time to submit documents.
The regulator’s detailed questions, however, show why the event attracted scrutiny.
The FSDA wanted to know what the products were, where they came from, whether they were legally approved, what claims were being made about them, whether participants would receive them and, if they were administered, who would administer them and under what medical safeguards.
For Upsurge Labs, the cancellation is being presented as a decision to pause and work with regulators, for the FSDA, the episode highlights a different question: when emerging biomedical products move from laboratories and clinical settings into wellness events, the identity, evidence, quality, regulatory status and manner of use cannot remain unclear.
For now, Bengaluru’s first proposed “Peptide Party” will not take place. The organisers say they are cooperating with the authorities, while the regulator has asked for the documents needed to determine exactly what was being proposed.
(Edited by Sumavarsha)
